TWA
WHWK

TCI Wealth Advisors’s Whitehawk Therapeutics WHWK Stock Holding History

TCI Wealth Advisors’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-409
Closed -$2.96K – 2333
2023
Q1 		$2.96K Buy
+409
New +$4.37K ﹤0.01% 1857

Other funds holding WHWK

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

TCI Wealth Advisors's WHWK Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Whitehawk Therapeutics (WHWK) in Q2 2023, closing a stake of 409 shares — an estimated $2.96K sold.

TCI Wealth Advisors first reported a position in WHWK in Q1 2023 and held it in 1 quarter. The position peaked at $2.96K in Q1 2023. 67 funds tracked by Wall St. Rank hold WHWK as of Q2 2023.

  • TCI Wealth Advisors reported no remaining Whitehawk Therapeutics position as of Q2 2023 after selling out during the quarter.
  • TCI Wealth Advisors sold 409 Whitehawk Therapeutics shares in Q2 2023, an estimated $2.96K.
  • TCI Wealth Advisors first reported a position in Whitehawk Therapeutics in Q1 2023 and held it in 1 quarter.
  • TCI Wealth Advisors's Whitehawk Therapeutics position peaked at $2.96K in Q1 2023.
  • 67 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.